327 related articles for article (PubMed ID: 25639219)
41. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract][Full Text] [Related]
42. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.
Väänänen RM; Lilja H; Kauko L; Helo P; Kekki H; Cronin AM; Vickers AJ; Nurmi M; Alanen K; Bjartell A; Pettersson K
Urology; 2014 Feb; 83(2):511.e1-7. PubMed ID: 24468524
[TBL] [Abstract][Full Text] [Related]
43. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
44. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
45. Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?
Smith SC; Tomlins SA
Clin Cancer Res; 2014 Sep; 20(18):4733-6. PubMed ID: 24944315
[TBL] [Abstract][Full Text] [Related]
46. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
Rickman DS; Chen YB; Banerjee S; Pan Y; Yu J; Vuong T; Perner S; Lafargue CJ; Mertz KD; Setlur SR; Sircar K; Chinnaiyan AM; Bismar TA; Rubin MA; Demichelis F
Neoplasia; 2010 Dec; 12(12):1031-40. PubMed ID: 21170267
[TBL] [Abstract][Full Text] [Related]
47. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
[TBL] [Abstract][Full Text] [Related]
48. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
49. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.
Schaefer G; Mosquera JM; Ramoner R; Park K; Romanel A; Steiner E; Horninger W; Bektic J; Ladurner-Rennau M; Rubin MA; Demichelis F; Klocker H
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):132-8. PubMed ID: 23381693
[TBL] [Abstract][Full Text] [Related]
50. ERG expression in prostate cancer: the prognostic paradox.
Taris M; Irani J; Blanchet P; Multigner L; Cathelineau X; Fromont G
Prostate; 2014 Nov; 74(15):1481-7. PubMed ID: 25175352
[TBL] [Abstract][Full Text] [Related]
51. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
52. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
53. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
Shah RB; Bentley J; Jeffery Z; DeMarzo AM
Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
[TBL] [Abstract][Full Text] [Related]
55. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
[TBL] [Abstract][Full Text] [Related]
56. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract][Full Text] [Related]
57. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.
Furusato B; van Leenders GJ; Trapman J; Kimura T; Egawa S; Takahashi H; Furusato M; Visakorpi T; Hano H
Pathol Int; 2011 Jul; 61(7):409-14. PubMed ID: 21707844
[TBL] [Abstract][Full Text] [Related]
59. [Expressions of TFF1 and TFF3 in prostate cancer and prostatic intraepithelial neoplasia and their clinical significance].
Liu M; Jin RS
Zhonghua Nan Ke Xue; 2015 Apr; 21(4):315-9. PubMed ID: 26027097
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.
Noh BJ; Sung JY; Kim YW; Chang SG; Park YK
Oncol Lett; 2016 Jun; 11(6):3621-3630. PubMed ID: 27284364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
